Latest European Markets News

Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.

Cash Converters has secured a £12 million growth facility from Lloyds Bank and agreed to acquire 10 UK franchise stores, marking a significant step in its UK expansion strategy.

ADX Energy has formalised licence amendments and identified four drill-ready shallow gas prospects in Upper Austria, targeting Q4 2025 for initial drilling. The company is advancing farm-in discussions to capitalise on a low-risk, pipeline-proximate gas opportunity in a sought-after European market.

Wellnex Life Limited reports a robust 46% revenue increase and successful AIM listing, setting the stage for UK and European expansion.

Patriot Battery Metals has announced a substantial upgrade to its Shaakichiuwaanaan Lithium Project, solidifying its position as the largest lithium pegmatite resource in the Americas and advancing its feasibility study on track for Q3 2025.

Neuren Pharmaceuticals reports a robust 11% rise in DAYBUE™ US net sales for Q1 2025, alongside a 17% jump in royalty income, setting the stage for an anticipated European market entry in early 2026.

Talga Group advances its European battery materials ambitions with EU Strategic Project recognitions for its graphite mine and anode refinery, alongside a €70 million Innovation Fund grant.

International Graphite's March 2025 quarterly report highlights strong geopolitical tailwinds and government backing for its Springdale Graphite Project and Collie processing facilities, positioning the company as a key player in the critical minerals supply chain.

Little Green Pharma reported a robust 40% revenue increase for FY25, driven by strong European sales and the strategic acquisition of Health House. The company also advanced clinical research and secured new therapy funding, positioning itself for continued growth.

Castile Resources has added critical mineral bismuth as a by-product to its Rover 1 Bankable Feasibility Study, leveraging a dramatic price surge driven by Chinese export restrictions.

Elementos Limited has delivered a robust Definitive Feasibility Study for its Oropesa Tin Project in Spain, secured key partnerships, and commenced new drilling at its Cleveland Project in Tasmania, all against a backdrop of rising tin prices driven by global supply disruptions.

Medical Developments International reported a robust Q3 FY25 with $8.9 million revenue and $1.7 million operating cashflow, driven by strong Penthrox demand and pricing. New distribution agreements in France and Switzerland position the company for further European expansion.